27/11/2023Published by Fondazione Gianni Bonadonna at 27/11/2023Categories Events UncategorizedOral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
20/11/2023Published by Fondazione Gianni Bonadonna at 20/11/2023Categories Events UncategorizedPembrolizumab plus enfortumab vedotin in bladder cancer
13/11/2023Published by Fondazione Gianni Bonadonna at 13/11/2023Categories Events UncategorizedMolecular features of high proliferation/low ER-related signaling breast cancers suggest more effective therapeutic strategies
06/11/2023Published by Fondazione Gianni Bonadonna at 06/11/2023Categories Events UncategorizedClinical outcomes of luminal-like breast cancers with estrogen receptors loss at metastatic relapse
30/10/2023Published by Fondazione Gianni Bonadonna at 30/10/2023Categories Events UncategorizedSacituzumab govitecan in ER+/HER2- metastatic breast cancer
23/10/2023Published by Fondazione Gianni Bonadonna at 23/10/2023Categories Events UncategorizedIpilimumab with or without nivolumab in refractory metastatic melanoma
16/10/2023Published by Fondazione Gianni Bonadonna at 16/10/2023Categories Events UncategorizedThe analysis of thousands of cancer and normal tissue gene expression profiles can guide clinical development of antibody-drug coniugates in the right patient population
09/10/2023Published by Fondazione Gianni Bonadonna at 09/10/2023Categories Events UncategorizedNeratinib, fulvestrant and trastuzumab in HER2-mutant metastatic breast cancer
02/10/2023Published by Fondazione Gianni Bonadonna at 02/10/2023Categories Events UncategorizedSelpercatinib in thyroid and other tumors
